Friday, June 21, 2013

GI CANCERS UPDATE

*Following CEA every 3 months and CT once every year was compared to CT every 6 months -no difference in progression free survival or OS,
*Maintenance Xeloda and Avastin in Metastatic Colorectal cancer?  read CAIRO3 by the Dutch!
*"An interesting negative study from Charles Loprinzi and his colleagues[4] looked at the impact of infused magnesium and calcium on the prevention of the sensory neurotoxicity associated with oxaliplatin and found no benefit. This was a large, well-designed study that leaves that myth to rest, which may be of benefit in some way." DAVID KERR.
*Abraxane -gemzar a new standard in metastatic pancreatic cancer!

No comments: